Skip to main content

Individual Drug Analyses

This page contains a complete list of all FDA analyses conducted in the Sentinel System from the start of Mini-Sentinel in 2009 to the present. 

The table below is organized at the individual analysis level (e.g., Level 1, Level 2, Query Builder, protocol-based assessment, etc.). It is designed to support searches for a specific analysis. 

Alternatively, the Drug Studies table groups together related analyses that FDA conducted to address a safety concern, or set of related safety concerns. The Drug Studies page also provides important background information and describes the regulatory impact.

Note: The appearance of a drug in a Sentinel study does not mean that FDA has concluded that a causal relationship exists between the drug and the health outcome of interest. Patients and healthcare providers should refer to FDA.gov for further information about drug safety.

FDA Sentinel Analyses from ARIA and Other Sentinel Data Sources

Title Medical Product Outcomes Date
Characterization of Pediatric Demographics and Enrollment in the Sentinel Distributed Database: An Updated Descriptive Analysis
Descriptive
Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: An Updated Descriptive Analysis
TriNetX Analysis
new molecular entities (NMEs)
Utilization of Beta Blockers in the Pediatric Population: A Follow Up Updated Descriptive Analysis
Descriptive
Concomitant Use of Medications with Drug-Drug Interactions with Nirmatrelvir and Ritonavir Among Patients Treated with Nirmatrelvir and Ritonavir or Patients with COVID-19: A Descriptive Analysis
Descriptive
nirmatrelvir and ritonavir
Utilization of Ibrexafungerp in Pregnant Patients: An Updated Descriptive Analysis in TriNetX
TriNetX Analysis
Duration of Follow Up for New Molecular Entities Approved in 2007: A Descriptive Analysis
Summary Table
new molecular entities (NMEs)
Interstitial Lung Disease (ILD) in Patients with Inflammatory Bowel Disease (IBD) and Following Vedolizumab or Natalizumab Initiation: A Descriptive Analysis
Descriptive
natalizumab,
vedolizumab
interstitial lung disease
Interstitial Lung Disease (ILD) Rates in Patients with Inflammatory Bowel Disease (IBD) and Following IBD Advanced Therapy: A Descriptive Analysis
Descriptive
adalimumab,
certolizumab,
etrasimod,
golimumab,
infliximab,
mirikizumab,
ozanimod,
risankizumab,
tofacitinib,
upadacitinib,
ustekinumab
interstitial lung disease
Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: An Interrupted Time Series Analysis
Retrospective Inferential
Validation of Hospitalized COVID-19 Diagnosis Detected from Claims-Based Algorithms: A Descriptive Analysis
Site-Specific Query
Utilization of Products Over Time for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis
Descriptive
products for the development of the pregnancy safety study framework
use in pregnancy
Utilization of Loop Diuretics: A Descriptive Analysis
Descriptive
bumetanide,
loop diuretics
Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: A Descriptive Analysis
TriNetX Analysis
new molecular entities (NMEs)
Count and Duration of Follow-up of New-Onset Cancer: A Descriptive Analysis
Descriptive
Intentional Self-Harm Following Montelukast Use in Patients with Asthma: An Updated Analysis Using ICD-10-CM Coding
Retrospective Inferential
inhaled corticosteroids,
montelukast
intentional self-harm
Arterial and Venous Thrombotic Events in Patients with COVID-19 in Inpatient and Ambulatory Settings: A Descriptive Analysis
Descriptive
arterial thromboembolism
venous thromboembolism
Racial and Ethnic Differences in the Clinical Characteristics of Patients with Various Stages of COVID-19: A Descriptive Analysis
PCORnet Descriptive Analysis
Utilization and Coding Patterns of Long-Acting Injectable Antipsychotics (LAIA): A Descriptive Analysis
Descriptive
long-acting injectable antipsychotics
Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: A Descriptive Analysis
Descriptive
Gimoti (metoclopramide nasal spray)
Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: An Updated Descriptive Analysis
Descriptive
Gimoti (metoclopramide nasal spray)
Ustekinumab and Comparator Treatment Utilization and Pneumonia Outcomes in Patients with Crohn's Disease or Ulcerative Colitis: An Updated Descriptive Analysis
Descriptive
adalimumab,
infliximab,
ustekinumab,
vedolizumab
pneumonia (Chron's disease)
pneumonia (ulcerative colitis)
Capture of Long COVID in TriNetX: A Descriptive Analysis
TriNetX Analysis
post-acute COVID-19 syndrome
Occurrence of Stroke, Intracranial Hemorrhage, and Bleeding Outcomes Following Direct Oral Anticoagulant Use in Patients with Atrial Fibrillation: A Descriptive Analysis
Descriptive
apixaban,
dabigatran,
edoxaban,
rivaroxaban
gastrointestinal bleeding
intracranial hemorrhage
major extracranial bleeding
thromboembolic stroke
Counts and Characteristics of Long-Acting Injectable Antipsychotic (LAIA) Users: A Descriptive Analysis
Descriptive
long-acting injectable antipsychotics
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use in Patients with Diabetes Mellitus: A Descriptive Analysis
Descriptive
Outcome Monitoring Following Dupilumab Use: A Signal Identification Analysis
Signal Identification
Mixed Amphetamine Salts Immediate-Release Tablet Use: A Descriptive Analysis
Descriptive
mixed amphetamine salts immediate-release tablets
Outcome Monitoring Following Baloxavir Use: A Signal Identification Analysis
Signal Identification
Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: A Descriptive Analysis
Descriptive
Pediatric Use of Drug Device Combinations: A Descriptive Analysis
Descriptive
Lipiodol (Ethiodized Oil) and Other Non-Oil Based Iodine Imaging Agent Utilization Patterns: A Descriptive Analysis
Descriptive
Lipiodol (ethiodized oil)
Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: An Updated Descriptive Analysis
Descriptive
brodalumab,
guselkumab,
risankizumab,
tildrakizumab
Counts and Characteristics of Pegylated Liposomal Doxorubicin and Non-Liposomal Doxorubicin Users: A Descriptive Analysis
Descriptive
non-liposomal doxorubicin,
pegylated liposomal doxorubicin
Characterization of Cannabis-Derived Product Users in the National Patient-Centered Clinical Research Network (PCORnet): A Descriptive Analysis
PCORnet Descriptive Analysis
cannabis-derived products
Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis
Retrospective Inferential
armodafinil,
modafinil
non-cardiac congenital malformations
Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) that Employ Elements to Assure Safe Use (ETASU): A Descriptive Analysis
Descriptive
alosetron,
alvimopan,
clozapine,
collagenase clostridium histolyticum,
denosumab,
eculizumab,
idelalisib,
isotretinoin,
lenalidomide,
mifepristone,
mycophenolate,
natalizumab,
olanzapine extended release,
panobinostat,
phentermine/​topiramate,
pomalidomide,
romiplostim,
teduglutide,
testosterone undecanoate,
vigabatrin
Racial and Ethnic Differences in COVID-19 Treatment and Mortality in TriNetX: A Descriptive Analysis
TriNetX Analysis
Utilization, Dispensing, and Coding Patterns of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis
Descriptive
Neulasta (pegfilgrastim),
Neupogen (filgrastim),
Remicade (infliximab)
COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis
Retrospective Inferential
proton pump inhibitors
COVID-19 hospitalization
Severe COVID-19
Characterization of Use of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis
Descriptive
Neupogen (filgrastim),
Remicade (infliximab)
Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis
Descriptive
Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers Linked to Live-Birth Deliveries in the Mother-Infant Linkage Table: A Descriptive Analysis
Descriptive
products for the development of the pregnancy safety study framework
use in pregnancy
Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis
Descriptive
products for the development of the pregnancy safety study framework
use in pregnancy
Baloxavir and Oseltamivir Utilization: A Descriptive Analysis
Descriptive
baloxavir,
oseltamivir
Bevacizumab and Other Cancer Medication Use in Pregnant Patients: A Descriptive Analysis
Summary Table
bevacizumab,
pegaptanib,
ranibizumab,
verteporfin
Incident Utilization of Allopurinol, Hydralazine, and Propylthiouracil: A Descriptive Analysis
Summary Table
allopurinol,
hydralazine,
propylthiouracil
Incident Utilization Patterns of Obesity Drugs: A Descriptive Analysis
Summary Table
Utilization and Switching Patterns of Mixed Amphetamine Salt (MAS) Products in Patients with Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy: A Descriptive Analysis
Descriptive
mixed amphetamine salts
switching patterns
Utilization of Beta Blockers in the Pediatric Population: An Updated Descriptive Analysis
Descriptive
Utilization of Beta Blockers in the Pediatric Population: A Descriptive Analysis
Descriptive
Characterization of Cannabis-Derived Product Users in TriNetX: Four Descriptive Analyses
TriNetX Analysis
cannabis-derived products
Baricitinib or Tocilizumab Use in Hospitalized Patients with a COVID-19 Diagnosis: A Descriptive Analysis
PCORnet Descriptive Analysis
baricitinib,
tocilizumab
emergency use authorization (EUA) utilization
Prevalence and Characterization of Pharmacogenetic Testing Healthcare Common Procedure Coding System (HCPCS) Procedure Codes in the Mini-Sentinel Distributed Database (MSDD): A Descriptive Analysis
Summary Table
pharmacogenetic testing
Dupixent (Dupilumab) Utilization Patterns: A Descriptive Analysis
Descriptive
Alosetron and Eluxadoline Use: A Descriptive Analysis
Descriptive
alosetron,
eluxadoline
Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis
Descriptive
renal cell carcinoma
Outcome Monitoring Following Erenumab Use: A Signal Identification Analysis
Signal Identification
Mortality Following Long-Acting Injectable Antipsychotics Use in Patients with Dementia: An Inverse Probability of Treatment Weighting Analysis
Retrospective Inferential
long-acting injectable antipsychotics
Biologics Use in Adults with Ulcerative Colitis: A Descriptive Analysis
Descriptive
adalimumab,
golimumab,
infliximab,
vedolizumab
Ischemic Colitis Following Alosetron Use: A Descriptive Analysis
Descriptive
ischemic colitis
Utilization and Switching Patterns of Inhaled Corticosteroid/Long Acting Beta Agonist and Advair Diskus in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Descriptive Analysis
Descriptive
Advair Diskus,
fluticasone salmeterol
brand to generic switching
Brand to Generic Switching Patterns Among Advair Diskus Users with Asthma or Chronic Obstructive Pulmonary Disease (COPD): A Descriptive Analysis
Descriptive
Advair Diskus,
fluticasone salmeterol
brand to generic switching
Insulin Coding Practices: A Descriptive Analysis
Descriptive
Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Matched Analysis
Retrospective Inferential
sacubitril/​valsartan
Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis
Retrospective Inferential
sacubitril/​valsartan
Use of Gonadotropin-Releasing Hormone (GnRH) Agonists in Patients with Gender Dysphoria: A Descriptive Analysis
Descriptive
gonadotropin-releasing hormone agonists
duration of use
Utilization of Select Products for Migraine Treatment and Prevention: A Descriptive Analysis
Descriptive
eptinezumab,
erenumab-aooe,
fremanezumab,
galcanezumab,
rimegepant,
ubrogepant
Utilization of Select Biological Products: A Descriptive Analysis
Descriptive
Avastin (bevacizumab),
Epogen (epoetin alfa),
Inflectra (infliximab-dyyb),
Mvasi (bevacizumab-awwb),
Neupogen (filgrastim),
Remicade (infliximab),
Renflexis (infliximab-abda),
Retacrit (epoetin alfa-epbx),
Zarxio (filgrastim-sndz),
Zirabev (bevacizumab-bvzr)
Outcome Monitoring Following Zarxio Use: An Updated Signal Identification Analysis
Signal Identification
Zarxio (filgrastim-sndz)
Congenital Malformations Observed in the Mother’s or Linked Infant’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis
Descriptive
all congenital malformations
congenital cardiac malformations (primary)
congenital urinary malformations (primary)
Congenital Malformations Observed in the Mother’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis
Descriptive
all congenital malformations
congenital cardiac malformations (primary)
congenital urinary malformations (primary)
Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: A Descriptive Analysis
Descriptive
atrioventricular block
heart failure
permanent pacemaker placement
septal myectomy
ventricular arrhythmia
Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: An Updated Descriptive Analysis
Descriptive
atrioventricular block
heart failure
myocardial infarction
permanent pacemaker placement
septal myectomy
ventricular arrhythmia
Characterization of Patients and Encounters in the TriNetX Live USA Network: A Descriptive Analysis
TriNetX Analysis
Identifying Potential Risk Factors for Respiratory Failure: A Covariate Stratified Analysis
Retrospective Inferential
acute respiratory failure
Exploring Claims-Based Definitions of, and Characterizing Patients with, Respiratory Failure: A Descriptive Analysis
Descriptive
acute respiratory failure
Utilization of Ixekizumab in Pregnant Patients: A Descriptive Analysis
Descriptive
Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification Analysis
Signal Identification
Ozempic (semaglutide)
Outcome Monitoring Following Zarxio Use: A Signal Identification Analysis
Signal Identification
Zarxio (filgrastim-sndz)
Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis in TriNetX
TriNetX Analysis
Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis
Retrospective Inferential
any fracture
hip replacement
major fracture (primary)
temporomandibular joint replacement
Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis (A Follow-up to a Previous Analysis)
Retrospective Inferential
any fracture
hip replacement
major fracture (primary)
temporomandibular joint replacement
Comparative Effectiveness of Azithromycin Relative to Roflumilast in Individuals With Uncontrolled Chronic Obstructive Pulmonary Disease Despite Triple Inhaled Therapy
azithromycin,
roflumilast
hospitalization and death
Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis
Descriptive
bamlanivimab,
bamlanivimab etesevimab,
casirivimab imdevimab
Differences in COVID-19 Testing, Positivity, Hospitalization, and Mortality by Race and Ethnicity in the Sentinel Distributed Database: A Descriptive Analysis
Descriptive
Utilization of Obesity Drugs: A Descriptive Analysis
Descriptive
Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis
Descriptive
bamlanivimab,
bamlanivimab etesevimab,
casirivimab imdevimab,
sotrovimab
anaphylaxis
hospitalization
Utilization of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitor Drugs: A Descriptive Analysis
Summary Table
obesity drugs,
sodium-glucose co-transporter-2 (SGLT-2) inhibitor
Characterization of Infants in the Mother-Infant Linkage Table in the Sentinel Distributed Database: A Descriptive Analysis
Descriptive
Seizures Following Gadolinium-Based Contrast Agents Exposure: A Self-Controlled Risk Interval Analysis
Retrospective Inferential
gadolinium-based contrast agents (GBCA)
Tacrolimus Use in Patients Following Liver or Kidney Transplants: A Descriptive Analysis
Descriptive
Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis
Descriptive
bamlanivimab,
bamlanivimab etesevimab,
casirivimab imdevimab
Count and Duration of Follow-up of New-Onset Cancer: An Updated Descriptive Analysis
Descriptive
Characterizing Pregnant Women With and Without Evidence of Heart Failure and Non-Pregnant Women With Heart Failure: A Propensity Score Matched Analysis
Retrospective Inferential
Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis
Descriptive
bamlanivimab,
bamlanivimab etesevimab,
casirivimab imdevimab
Outpatient Corticosteroid Use in Patients With COVID-19: An Updated Descriptive Analysis
Descriptive
Outpatient Corticosteroid Use in Patients With COVID-19: A Descriptive Analysis
Descriptive
Serious Infection Following Ustekinumab Use in Patients with Crohn’s Disease or Ulcerative Colitis: A Descriptive Analysis
Descriptive
adalimumab,
infliximab,
ustekinumab,
vedolizumab
serious infection (Crohn’s disease)
serious infection (ulcerative colitis)
Characterization of Pediatric Demographics and Enrollment in the Sentinel Distributed Database: A Descriptive Analysis
Descriptive
Death Data Exploration: A Descriptive Analysis
Custom Code
Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use in Patients Aged 65 or Older: An Inverse Probability of Treatment Weighting (IPTW) Analysis
Retrospective Inferential
apixaban,
dabigatran,
rivaroxaban
gastrointestinal bleeding
intracranial hemorrhage
major extracranial bleeding
thromboembolic stroke
Incidence and Prevalence of Confounding Variables Over Time in the Sentinel Distributed Database (SDD): A Descriptive Analysis
Descriptive
Duration of Follow Up for New Molecular Entities Approved in 2018: A Descriptive Analysis
Descriptive
new molecular entities (NMEs)
Counts and Characteristics of Individuals With Drug-Device Combination Use: A Descriptive Analysis
Descriptive
drug device combinations
Utilization of Brodalumab: A Descriptive Analysis
Descriptive
Estimated Prevalence of Glomerular Diseases: An Updated Descriptive Analysis
Descriptive
glomerular diseases
Estimated Prevalence of Glomerular Diseases: A Descriptive Analysis
Descriptive
glomerular diseases
Hydroxyurea Use Among Patients with Sickle Cell Disease (SCD): A Descriptive Analysis
Descriptive
Epidiolex (prescription cannabidiol) Utilization Patterns: A Descriptive Analysis
Descriptive
Epidiolex (prescription cannabidiol)
Valganciclovir Use in Children with Congenital Cytomegalovirus Disease (cCMV) or Cytomegalovirus (CMV) Infection: A Descriptive Analysis
Descriptive
Incident and Prevalent Use of Loop Diuretics: A Descriptive Analysis
Descriptive
Human Epidermal Growth Factor Receptor 2 (HER2) Antagonist Use in Patients with Live Birth Deliveries: A Descriptive Analysis
Descriptive
Drug Utilization Over Time for Six Drug Classes
Descriptive
ace inhibitors,
beta blockers,
granulocyte colony-stimulating factor (GC-SF),
intravenous (IV) iron,
statins,
tumor necrosis factor (TNF) alpha inhibitor
Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: A Descriptive Analysis
Descriptive
mometasone sinus implant
Incidence and Prevalence of N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) Contaminated Valsartan Use: A Descriptive Analysis
Descriptive
Bleeding Events and Venous Thromboembolism (VTE) following Enoxaparin Use: A Descriptive Analysis
Descriptive
hospitalized bleeding
major bleeding
venous thromboembolism (VTE)
Tofacitinib, Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Tumor Necrosis Factor Inhibitors (TNFi) Use: A Descriptive Analysis
Descriptive
disease-modifying anti-rheumatic drugs (DMARDs),
tofacitinib,
tumor necrosis factor inhibitors (TNFi)
N‐nitrosodimethylamine (NDMA)‐Contaminated and Non‐NDMA‐Contaminated Valsartan Use: A Descriptive Analysis
Descriptive
Duration of Follow Up for New Molecular Entities Approved in 2019: A Descriptive Analysis
Descriptive
new molecular entities (NMEs)
Duration of Follow Up for New Molecular Entities Approved in 2017: An Updated Descriptive Analysis
Descriptive
new molecular entities (NMEs)
Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis
Retrospective Inferential
hospitalized depression
intentional self-harm
Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis (A Follow-up to a Previous Analysis)
Retrospective Inferential
hospitalized depression
intentional self-harm
Racial Differences in COVID-19 Outcomes (2020-2021)
Retrospective Inferential
Critical COVID-19
death
hospitalization with COVID-19
Use of Multiple Sclerosis Drugs Among Pregnant Women with Live-Birth Deliveries: A Descriptive Analysis
Descriptive
alemtuzumab,
cladribine,
dalfampridine,
dimethyl fumarate,
diroximel fumarate,
fingolimod,
glatiramer acetate,
interferon beta-1A,
interferon beta-1B,
mitoxantrone,
natalizumab,
ocrelizumab,
peginterferon beta-1a,
siponimod,
teriflunomide
Oral Metoclopramide Use: A Descriptive Analysis
Descriptive
Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) that Employ Elements to Assure Safe Use (ETASU)
Summary Table
drugs with REMS that employ ETASU
Duration of Follow Up for New Molecular Entities Approved in 2017: A Descriptive Analysis
Descriptive
new molecular entities (NMEs)
Brand and Generic Tacrolimus Use following Kidney, Heart, and Liver Transplants: A Descriptive Analysis
Descriptive
Incidence Rate of Severe Uterine Bleeding Among New Users of Oral Anticoagulants: A Descriptive Analysis
Descriptive
apixaban,
dabigatran,
oral anticoagulant,
rivaroxaban,
warfarin
severe uterine bleed
Utilization of Sacubitril/Valsartan: A Descriptive Analysis
Descriptive
sacubitril/​valsartan
Duration of Follow Up for New Molecular Entities Approved in 2011
Descriptive
new molecular entities (NMEs)
Patterns in Insulin Product Use and Billing Codes: A Descriptive Analysis
Descriptive
Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007
Descriptive
new molecular entities (NMEs)
Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009
Descriptive
new molecular entities (NMEs)
Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013
Descriptive
new molecular entities (NMEs)
Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015
Descriptive
new molecular entities (NMEs)
Duration of Follow Up for New Molecular Entities Approved in 2016
Descriptive
new molecular entities (NMEs)
Follow-Up Time for Guselkumab, Risankizumab, and Tildrakizumab Users with Plaque Psoriasis: A Descriptive Analysis
Descriptive
guselkumab,
risankizumab,
tildrakizumab
Angioedema following Dipeptidyl Peptidase IV (DPP IV) Inhibitors and Angiotensin Converting Enzyme (ACE) Inhibitors Use: A Descriptive Analysis
Mini-Sentinel
angiotensin-converting enzyme (ACE) inhibitor,
dipeptidyl peptidase-IV (DPP-IV) inhibitor
Venous and Arterial Thromboembolism among New Users of NuvaRing and Other Combined Hormonal Contraceptives: A Descriptive Analysis
Descriptive
combined hormonal contraceptives (CHCs),
ethinyl estradiol (EE),
NuvaRing
arterial thromboembolism (ATE)
venous thromboembolism (VTE)
Counts of Individuals in the Sentinel Distributed Database
Descriptive
Characterization of Mothers in the Mother-Infant Linkage Table in the Sentinel Distributed Database: A Descriptive Analysis
Descriptive
Pregnancy among Women with Heart Failure: A Descriptive Analysis
Descriptive
Serious Infections among Immunocompromised Health Plan Members
Descriptive
serious infection
Cutaneous Small-Vessel Vasculitis following Dabigatran, Rivaroxaban, and Apixaban Use in Patients with Atrial Fibrillation: A Propensity Score Matched Analysis
Retrospective Inferential
apixaban,
dabigatran,
direct oral anticoagulant (DOAC),
rivaroxaban,
warfarin
cutaneous small-vessel vasculitis
Direct Oral Anticoagulants (DOACs), Warfarin, Allopurinol, or Propylthiouracil Use in Patients with Cutaneous Small-Vessel Vasculitis: A Descriptive Analysis
Descriptive
allopurinol,
direct oral anticoagulant (DOAC),
propylthiouracil,
warfarin
cutaneous small-vessel vasculitis
Prevalent and Incident Drug Use in a Pediatric Population: A Descriptive Analysis
Mini-Sentinel
acetaminophen with codeine,
acyclovir,
acyclovir sodium,
albuterol,
albuterol sulfate,
levalbuterol HCL,
levalbuterol tartrate,
nitazoxanide,
nizatidine,
oxycodone HCL,
sucralfate
Abacavir, Carbamazepine, Clopidogrel, and Phenytoin Use: A Descriptive Analysis
Mini-Sentinel
abacavir,
carbamazepine,
clopidogrel,
phenytoin
Incidence of Acute Respiratory Failure (ARF) following Trimethoprim-Sulfamethoxazole (TMP-SMX) Use: A Descriptive Analysis
Descriptive
trimethoprim-sulfamethoxazole
acute respiratory failure
Thrombotic Events and Death in Inpatient-Identified COVID-19 Patients
TriNetX Analysis
thrombotic events
Thrombotic Events in COVID-19 Patients Not Requiring Hospitalization at the Time of Diagnosis
TriNetX Analysis
thrombotic events
Ustekinumab Dispensing Patterns: A Descriptive Analysis
Descriptive
adalimumab,
certolizumab pegol,
infliximab,
ustekinumab,
vedolizumab
Risk of Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis
Retrospective Inferential
armodafinil,
modafinil
cardiac congenital malformations
Risk of Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Descriptive Analysis
Descriptive
armodafinil,
modafinil
cardiac congenital malformations
Counts of Individuals with Gout Using Urate-Lowering Therapy (ULT) and Switching between ULT Products: A Descriptive Analysis
Descriptive
allopurinol,
febuxostat
Incidence of Severe Uterine Bleed Following Novel Oral Anticoagulants Use: A Descriptive Analysis
Descriptive
apixaban,
dabigatran,
rivaroxaban,
warfarin
severe uterine bleed
Mini-Sentinel: Diabetic Ketoacidosis following Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors, Sulfonylureas, Saxagliptin, and Sitagliptin Use: A Descriptive Analysis
Descriptive
saxagliptin,
sitagliptin,
sodium-glucose cotransporter-2 (SGLT-2) inhibitor,
sulfonylurea
diabetic ketoacidosis
Thromboembolic Stroke, Intracranial Hemorrhage, Gastrointestinal Bleeding, and Major Extracranial Bleeding following Dabigatran, Rivaroxaban, and Apixaban Use in Patients with Atrial Fibrillation: A Propensity Score Matched Analysis
Retrospective Inferential
apixaban,
dabigatran,
non-vitamin K antagonist oral anticoagulants,
rivaroxaban
gastrointestinal bleeding
intracranial hemorrhage
major extracranial bleeding
thromboembolic stroke
Wrong Frequency Errors with Low Dose Oral Methotrexate
Descriptive
Factors Related to the Assignment of Sodium Glucose Cotransporter-2 Inhibitors (SGLT-2i) versus Dipeptidyl Peptidase-4 Inhibitors (DPP-4i)
Retrospective Inferential
sodium-glucose cotransporter-2 (SGLT-2) inhibitor
factors for treatment assignment
Frequency of Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) and Estimated Incidence Rates of Post-PTSMA Cardiovascular Outcomes: A Descriptive Analysis
Descriptive
percutaneous transluminal septal myocardial ablation
Acute Myocardial Infarction and Heart Failure following Saxagliptin or Sitagliptin Use: A Propensity Score Matched Analysis
Retrospective Inferential
long-acting insulin,
pioglitazone,
saxagliptin,
second-generation sulfonylurea,
sitagliptin
acute myocardial infarction (AMI)
heart failure
Stroke, Intracranial Hemorrhage, and Bleeding following Dabigatran, Rivaroxaban, and Apixaban Use in Patients Aged 65 or Older: A Propensity Score Matched Analysis
Retrospective Inferential
apixaban,
dabigatran,
rivaroxaban
bleeding event
intracranial hemorrhage
stroke
Cutaneous Small-Vessel Vasculitis following Direct Oral Anticoagulants (DOACs), Warfarin, or Allopurinol Use in Patients with Atrial Fibrillation: A Descriptive Analysis
Descriptive
allopurinol,
direct oral anticoagulant (DOAC),
warfarin
cutaneous small-vessel vasculitis
Same Day Seizures following Gadolinium Based Contrast Agents: A Self-Controlled Risk Interval Analysis
Custom Code
gadolinium-based contrast agent (GBCA)
Ranitidine Drug Utilization Patterns
Descriptive
Intravenous (IV) Iron Utilization Among Pregnant Women
Descriptive
intravenous (IV) iron
Algorithms to Estimate Start of Pregnancy Using In-Vitro Fertilization (IVF), Intrauterine Insemination (IUI), and Select Prenatal Tests among Pregnancies Resulting in a Live-Born Delivery
Descriptive
Mini-Sentinel: Availability of International Normalized Ratio (INR) Laboratory Test Values and INR Test Procedures among New Warfarin Users
Descriptive
Spironolactone Use in Patients with Reduced Ejection Fraction Heart Failure (HFrEF) or Preserved Ejection Fraction Heart Failure (HFpEF)
Descriptive
Sacubitril/Valsartan, Angiotensin-Converting Enzyme (ACE) Inhibitors, and Other Angiotensin II Receptor Blockers (ARBs) Use in Patients with Heart Failure
Descriptive
angiotensin II receptor blocker (ARB),
angiotensin-converting enzyme (ACE) inhibitor,
sacubitril/​valsartan
Mini-Sentinel: Switching Between Generic and Brand Clonazepam
Mini-Sentinel
Glaucoma, Cataracts, Diminished Visual Acuity, and Nasal Septal Perforation following Mometasone Sinus Implant Use in Patients with Nasal Polyposis: A Descriptive Analysis
Descriptive
cataracts
diminished visual acuity
glaucoma
nasal septal perforation
Hypertension in Pediatric Patients: A Descriptive Analysis
Descriptive
Use of Typical and Atypical Antipsychotics Among Infants
Custom Code
antipsychotic,
atypical antipsychotic,
typical antipsychotic
Characterization of SGLT-2 Inhibitor Users in the Patient-Centered Clinical Research Network (PCORnet)
PCORnet Descriptive Analysis
sitagliptin,
sodium-glucose cotransporter-2 (SGLT-2) inhibitor
Non-Melanoma Skin Cancer following Hydrochlorothiazide Use: A Propensity Score Matched Analysis
Retrospective Inferential
hydrochlorothiazide (HCTZ)
non-melanoma skin cancer
Total Enrollment with Medical and Drug Coverage
Summary Table
Trends in Penicillin Allergy Testing
Descriptive
penicillin allergy test
Time Until Guillain-Barré Syndrome or Bell's Palsy Diagnosis following Initiation of Checkpoint Inhibitor Treatment
Descriptive
atezolizumab,
avelumab,
durvalumab,
ipilimumab,
nivolumab,
pembrolizumab
Bell’s palsy
Guillain-Barré syndrome
Prenatal Tests in Women with Potential Stillbirths
Descriptive
Concurrent Use of Ticagrelor with Atorvastatin or Rosuvastatin
Descriptive
atorvastatin,
rosuvastatin,
ticagrelor
Duration of Follow-up for Individuals with Chronic Conditions
Descriptive
Alzheimer's disease
acquired hypothyroidism
acute myocardial infarction (AMI)
anemia
asthma
atrial fibrillation
benign prostatic hyperplasia
breast cancer
bronchiectasis
chronic conditions
chronic kidney disease (CKD)
chronic obstructive pulmonary disease
colorectal cancer
depression
diabetes
endometrial cancer
glaucoma
heart failure
hyperlipidemia
hypertension
ischemic heart disease
lung cancer
osteoarthritis
osteoporosis
prostate cancer
rheumatoid arthritis
stroke
transient ischemic attack (TIA)
Use of Metoclopramide among Patients with Diabetic Gastroparesis and Type 2 Diabetes
Descriptive
duration of use
Hydroxyurea Use in Patients with Sickle Cell Anemia
Descriptive
sickle cell anemia
use by indication
Mini-Sentinel: Summary of Antidiabetic Agent Use During Pregnancy
Custom Code
alpha-glucosidase inhibitor,
amylin analog,
biguanide,
dipeptidyl peptidase-4 (DPP-4) inhibitor,
glucagon-like peptide-1 (GLP-1) receptor agonists,
injectable insulin,
meglitinide analog,
sulfonylurea,
thiazolidinedione
exposure in pregnancy
Epidemiology of Pediatric Respiratory Syncytial Virus-Associated Illness in FDA’s Sentinel System
Descriptive
respiratory syncytial virus (RSV)
respiratory syncytial virus-associated illness
Estimating Optimal Quantities for Initial Opioid Analgesic Prescriptions for Acute Pain Conditions Presenting to Surgical Settings
Custom Code
drug refill probability
Respiratory Syncytial Virus in a Pediatric Population
Descriptive
respiratory syncytial virus (RSV)
Hydroxyprogesterone Caproate and Progesterone Use During Pregnancy
Descriptive
hydroxyprogesterone caproate,
progesterone
exposure in pregnancy
Neuropsychiatric Events Following Montelukast Use: A Propensity Score Matched Analysis
Retrospective Inferential
inpatient depressive disorder
outpatient depressive disorder
self-harm
suicide
Multiple Sclerosis Relapses among Copaxone, Glatopa, Gilenya, and Glatiramer Users
Descriptive
Copaxone,
Gilenya,
glatiramer,
Glatopa
multiple sclerosis relapse
Cutaneous Small Vessel Vasculitis and Acute Kidney Injury Following Direct-Acting Oral Anticoagulant Use
Descriptive
direct oral anticoagulant (DOAC)
acute kidney injury
cutaneous small-vessel vasculitis
Non-Melanoma Skin Cancer following Hydrochlorothiazide Use
Descriptive
bendroflumethiazide (BFMTZ),
chlorothiazide (CTZ),
hydrochlorothiazide (HCTZ)
non-melanoma skin cancer
Sinus Stents with Mometasone and Diminished Visual Acuity
Descriptive
intranasal steroid,
mometasone,
oral steroid,
sinus stent
blindness
cataract surgery
cataracts
diminished visual acuity
glaucoma
Use of Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) in a Pediatric Population
Descriptive
angiotensin receptor blocker,
angiotensin-converting enzyme (ACE) inhibitor
Utilization Patterns of Qsymia (Phentermine/Topiramate)
Descriptive
phentermine HCl,
phentermine/​topiramate,
Qsymia,
topiramate
Use of Higher Dosage Strength Oral and Transmucosal Opioid Analgesics
Descriptive
higher dosage strength opioid analgesic,
lower dosage strength opioid analgesic,
opioid analgesic,
oral opioid analgesic,
transdermal opioid analgesic,
transmucosal opioid analgesic
Ischemic Stroke, Intracranial Hemorrhage, and Gastrointestinal Hemorrhage Among New Users of Apixaban and Warfarin
Descriptive
gastrointestinal hemorrhage
intracranial hemorrhage
ischemic stroke
Use of Korlym and Mifeprex (Mifepristone)
Descriptive
Korlym,
Mifeprex,
mifepristone
Antiemetic Use During Pregnancy
Custom Code
doxylamine,
granisetron,
metoclopramide HCL,
netupitant/​palonosetron HCl,
ondansetron,
palonosetron,
prochlorperazine,
promethazine HCl,
succinate/​pyridoxine HCl
exposure in pregnancy
Use of Valsartan, Angiotensin II Receptor Blockers (ARB), and Angiotensin-Converting Enzyme (ACE) Inhibitors
Descriptive
angiotensin II receptor blocker (ARB),
angiotensin-converting enzyme (ACE) inhibitor,
azilsartan medoxomil,
candesartan,
eprosartan,
irbesartan,
losartan,
olmesartan,
telmisartan,
valsartan
New Users of Oral Bisphosphonates
Mini-Sentinel
Neuropsychiatric Events following Montelukast Use
Descriptive
inhaled corticosteroid,
montelukast,
nasal corticosteroid,
zafirlukast
neuropsychiatric event
psychotropic medication use
suicide
Duration of Use Among New Users of Hydrochlorothiazide (HCTZ), Angiotensin-Converting Enzyme Inhibitors (ACEIs), and Angiotensin II Receptor Blockers (ARBs)
Descriptive
angiotensin II receptor blocker (ARB),
angiotensin-converting enzyme (ACE) inhibitor,
hydrochlorothiazide (HCTZ)
Severe Uterine Bleed Following Novel Oral Anticoagulants Use: A Propensity Score Analysis
Retrospective Inferential
apixaban,
dabigatran,
novel oral anticoagulant (NOAC),
rivaroxaban,
warfarin
severe uterine bleed
Leuprolide Acetate Use Among Patients with Central Precocious Puberty
Descriptive
central precocious puberty
Gadolinium-Based Contrast Agents (GBCAs) Use in Pregnancy
Descriptive
gadolinium-based contrast agent (GBCA)
exposure in pregnancy
Duration of Follow-Up and Treatment for Non-Insulin Antidiabetic Drugs
Descriptive
non-insulin antidiabetics
Dolutegravir Use During Pregnancy
Descriptive
exposure in pregnancy
Acute Myocardial Infarction and Stroke Among Patients with Testosterone-Related Indications
Mini-Sentinel
acute myocardial infarction (AMI)
stroke
Brintellix and Brilinta Medication Errors due to Name Confusion
Descriptive
Brilinta,
Brintellix
medication error
Characteristics of Gout Patients and Use of Urate-Lowering Therapies
Descriptive
urate-lowering therapies
SGLT-2 Inhibitor Use and Incidence of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus
Descriptive
canagliflozin,
dapagliflozin,
empagliflozin,
sitagliptin,
sodium-glucose cotransporter-2 (SGLT-2) inhibitor
diabetic ketoacidosis
Stroke, Gastrointestinal Bleeding, and Intracranial Hemorrhage Following Apixaban or Warfarin Use in Patients with Non-Valvular Atrial Fibrillation: A Propensity Score Matched Analysis
Retrospective Inferential
gastrointestinal (GI) bleed
intracranial hemorrhage
stroke
Optimal Initial Length of Opioid Prescription
Descriptive
Seizure Following Ranolazine Use
Retrospective Inferential
Use of Multiple Sclerosis Drugs Among Pregnant Women
Descriptive
alemtuzumab,
daclizumab,
dalfampridine,
dimethyl fumarate,
fingolimod,
glatiramer acetate,
interferon beta-1A,
interferon beta-1A/​albumin,
interferon beta-1B,
mitoxantrone,
natalizumab,
peginterferon beta-1a,
teriflunomide
Pulmonary Arterial Hypertension and Interstitial Lung Disease Events Among Interleukin Inhibitor Users
Descriptive
interleukin-1/-6 inhibitor
interstitial lung disease
pulmonary arterial hypertension
Duration of Use for Teriparatide
Descriptive
Quantifying Prevalence and Mortality Associated with Neonatal Enteroviral Sepsis (NES) Using Inpatient Data in FDA’s Sentinel System
Custom Code
neonatal enteroviral sepsis (NES)
COPD, Asthma, and Respiratory Disease Effectiveness (CARE) For 21st Century Cures: Feasibility Assessments for Comparative Effectiveness Studies
Custom Code
asthma
chronic obstructive pulmonary disease
Counts and Proportions of New Users of Fentanyl Transdermal System with Evidence of Prior Opioid Tolerance
Mini-Sentinel
fentanyl transdermal system
Phosphodiesterase Type 5 (PDE-5) Inhibitor Utilization Among Women
Descriptive
phosphodiesterase type 5 (PDE5) inhibitor
Sofosbuvir and Amiodarone Use and Bradycardia or Pacemaker Insertion
Descriptive
amiodarone,
sofosbuvir
bradycardia
pacemaker insertion
Algorithms Evaluating Dabigatran Use and Acute Myocardial Infarction Compared with Warfarin
Retrospective Inferential
dabigatran,
warfarin
acute myocardial infarction (AMI)
Use of Dabigatran and Intracranial Hemorrhage, Gastrointestinal Hemorrhage, Ischemic Stroke, and Acute Myocardial Infarction
Retrospective Inferential
acute myocardial infarction (AMI)
gastrointestinal hemorrhage
intracranial hemorrhage
ischemic stroke
New Pediatric Users of Leuprolide Acetate
Descriptive
Prevalence and Incidence of Progressive Multifocal Leukoencephalopathy (PML), Clostridium Difficile, and Cytomegalovirus (CMV) Diagnoses
Mini-Sentinel
clostridium difficile
cytomegalovirus (CMV)
progressive multifocal leukoencephalopathy (PML)
Incident Use of Selective Serotonin Reuptake Inhibitor Antidepressants
Mini-Sentinel
selective serotonin reuptake inhibitor (SSRI)
Identifying Suicide Codes in the Sentinel Distributed Database (SDD)
Custom Code
Clostridium difficile Infection Following Use of Vancomycin, Fidaxomicin, or Metronidzaole
Mini-Sentinel
fidaxomicin,
metronidazole,
vancomycin
clostridium difficile
Availability of International Normalized Ratio (INR) Laboratory Test Values and Test Procedures Among Warfarin Users
Mini-Sentinel
Warfarin Use Followed by International Normalized Ratio (INR) Lab Codes
Mini-Sentinel
Top Ten Causes of Death
Descriptive
Prevalent and Incident Use of Fingolimod
Mini-Sentinel
Risk of Acute Myocardial Infarction and Stroke among Carbidopa/Levodopa, Entacapone, and Carbidopa/Levodopa/Entacapone Users
Mini-Sentinel
carbidopa/​levodopa,
carbidopa/​levodopa/​entacapone (Stalevo),
entacapone
Prevalence and Incident Use of Promethazine
Mini-Sentinel
promethazine,
promethazine/​codeine,
promethazine/​phenylephrine/​codeine
Use of Clonazepam
Mini-Sentinel
Diagnosis of Agranulocytosis Following New Use of Anti-epileptic Drugs, Clozapine, and Olanzapine
Mini-Sentinel
carbamazepine,
clozapine,
lamotrigine,
levetiracetam,
ofatumumab,
olanzapine,
topiramate
agranulocytosis
Counts and Prevalence of Alendronate, Risedronate, Ibandronate, and Zolendronate
Summary Table
alendronate sodium,
alendronate sodium/​vitamin d3,
bandronate sodium,
calcitonin salmon,
calcitonin, salmon, synthetic,
denosumab,
ibandronate sodium,
raloxifene HCL,
risedronate sodium,
risedronate sodium/​calcium carbonate,
teriparatide,
zoledronic acid,
zoledronic acid reclast,
zoledronic acid/​mannitol and water,
zoledroniccid reclast,
zoledroniccid zometa
Counts and Prevalence of Linezolid and Vancomycin
Summary Table
linezolid,
vancomycin
Use of Atrial Fibrillation Drugs
Summary Table
dofetilide,
sotalol HCL
Incident Use of Hepatitis C Virus (HCV) Drugs
Summary Table
boceprevir,
ledipasivir/​sofosbuvir,
simeprevir sodium,
sofosbuvir,
telaprevir
Concomitancy and Indications for Idelalisib Use
Descriptive
bendamustine,
bortezomib,
chlorambucil,
cyclophosphamide,
doxorubicin,
ibritumomab,
ibrutinib,
idelalisib,
lenalidomide,
obinutuzumab,
ofatumumab,
prednisone,
rituximab,
vincristine
Prevalent and Incident Use of Generic Name Kinase Inhibitors
Summary Table
afatinib dimaleate,
axitinib,
bortezomib,
cabozantinib s-malate,
carfilzomib,
ceritinib,
crizotinib,
dabrafenib mesylate,
dasatinib,
erlotinib HCL,
everolimus,
gefitinib,
ibrutinib,
idelalisib,
imatinib mesylate,
lapatinib ditosylate,
nilotinib HCL,
pazopanib HCL,
ponatinib HCL,
regorafenib,
ruxolitinib phosphate,
sorafenib tosylate,
sunitinib malate,
trametinib dimethyl sulfoxide,
vandetanib,
vemurafenib
Incident Use of Rivaroxaban
Mini-Sentinel
Selected Medications and Death, with Linkage of Mini-Sentinel Distributed Database with NDI+
Mini-Sentinel
amiodarone,
amitriptyline,
amoxapine,
amoxicillin,
amoxicillin with clavulanate,
azithromycin,
cephalexin,
ciprofloxacin,
citalopram,
clarithromycin,
clindamycin,
clomipramine,
desipramine,
desvenlafaxine,
dofetilide,
doxepin,
dronedarone,
duloxetine,
erythromycin,
escitalopram,
flecainide,
fluoxetine,
fluvoxamine,
gemifloxacin,
imipramine,
levofloxacin,
levomilnacipran,
maprotiline,
mirtazapine,
moxifloxacin,
nefazodone,
norfloxacin,
nortriptyline,
ofloxacin,
paroxetine,
penicillin V,
propafenone,
protriptyline,
sertraline,
sotalol,
telithromycin,
trazodone,
trimethoprim-sulfamethoxazole,
trimipramine,
venlafaxine,
vilazodone,
vortioxetine
sudden cardiac death
Combined Oral Contraceptives Containing Ethinyl Estradiol and Levonorgestrel and Venous Thromboembolism
Descriptive
combined oral contraceptive (COC)
venous thromboembolism (VTE)
Venous Thromboembolism Following Continuous or Extended Cycle Contraceptive Use: A Propensity Score Matched Analysis
Retrospective Inferential
combined oral contraceptive (COC)
venous thromboembolism (VTE)
Counts, Prevalence, and Incidence of Intravenous (IV) Iron Products
Summary Table
ferumoxytol,
iron dextran complex,
iron sucrose complex,
sodium ferric gluconate complex
Exposure to Intravenous (IV) Iron Procedures and Anaphylaxis and Epinephrine Events
Mini-Sentinel
intravenous (IV) iron
anaphylaxis
epinephrine event
Rhabdomyolysis and/or Creatine Kinase Laboratory Results Following New Use of Statins or Angiotensin-Converting Enzyme Inhibitors
Descriptive
angiotensin-converting enzyme (ACE) inhibitor,
statin
creatine kinase laboratory result
rhabdomyolysis
Use of Tyrosine Kinase Inhibitors (TKIs)
Descriptive
axitinib,
pazopanib,
sorafenib,
sunitinib,
tyrosine kinase inhibitor
Length of Follow-up Time for New Users of Immunosuppressive Drugs
Retrospective Inferential
adalimumab,
alemtuzumab,
certolizumab,
dalfampridine,
dimethyl fumarate,
etanercept,
fingolimod,
glatiramer acetate,
golimumab,
infliximab,
interferon beta-1A,
interferon beta-1B,
mitoxantrone,
natalizumab,
pegylated interferon beta-1A,
teriflunomide,
ustekinumab
Prevalent and Incident Dispensings of Ranolazine
Summary Table
Boceprevir, Ledipasivir/Sofosbuvir, Simeprevir Sodium, Sofosbuvir, and Telaprevir Use
Summary Table
boceprevir,
ledipasivir/​sofosbuvir,
simeprevir sodium,
sofosbuvir,
telaprevir
Prevalent and Incident Use of SGLT2 Inhibitors
Descriptive
canagliflozin,
canagliflozin/​metformin HCl,
dapagliflozin propanediol,
dapagliflozin/​metformin HCl,
empagliflozin,
empagliflozin/​linagliptin
Concomitant Use of Opioid Analgesics and Cytochrome P450 (CYP) Inhibitors and Inducers
Summary Table
CYP inducer,
CYP inhibitor,
oxycodone,
oxymorphone
Metabolic Effects of Second Generation Antipsychotics in Youth, Subprojects 1, 2, and 3
Custom Code
aripiprazole,
olanzapine,
quetiapine,
risperidone,
second generation antipsychotic (SGA)
metabolic syndrome
type 2 diabetes mellitus
weight gain
Antiepileptic Drug (AED) Injection Procedure Codes
Retrospective Inferential
anti-epileptic drug (AED)
PROMPT: Rivaroxaban Surveillance
Summary Table
rivaroxaban,
warfarin
gastrointestinal (GI) bleed
intracranial hemorrhage
ischemic stroke
Drug and Medical Enrollment Counts
Summary Table
Counts of Commonly Used Angiostensin-Converting Enzyme (ACE) Inhibitors and Beta Blockers
Summary Table
angiotensin-converting enzyme (ACE) inhibitor,
beta blocker
A Protocol for Assessment of Dabigatran and Selected Safety Outcomes
Retrospective Inferential
dabigatran,
warfarin
intracranial hemorrhage
ischemic stroke
major extracranial hemorrhage
Use of Tumor Necrosis Factor (TNF) Blocker Drugs
Summary Table
tumor necrosis factor (TNF) blocker
Characterization of Pediatric Medical Conditions: Respiratory Syncytial Virus (RSV) Associated Illness
Descriptive
respiratory syncytial virus (RSV)
Molecularly Targeted Anti-Cancer Therapies
Summary Table
axitinib,
bicalutamide,
crizoatinib,
dasatinib,
erlotinib HCL,
everolimus,
gefitinib,
imatinib mesylate,
lapatinib ditosylate,
nilotinib HCL,
pazopanib HCL,
ruxolitinib phosphate,
sorafenib tosylate,
sunitinib malate,
tamoxifen citrate,
vandetanib,
vemurafenib,
vismodegib
Stroke Diagnosis Codes
Summary Table
Length of Enrollment in Pediatric Population
Descriptive
Prevalent and Incident Use of Isotretinoin
Summary Table
Occurrence of Selected Generic Drugs 13
Summary Table
amlodipine besylate,
efalizumab,
ibandronate sodium,
lamotrigine,
leflunomide,
maraviroc,
metoclopramide HCL,
nitrofurantoin,
nitrofurantoin macrocrystal,
nitrofurantoin monohyd/​m-crystal,
propylthiouracil,
quinine,
quinine sulfate,
ramipril,
rosiglitazone maleate,
sibutramine HCL m-hydrate,
tadalafil,
varenicline tartrate
Clostridium Difficile Prevalence and Vancomycin, Fidaxomicin, and Tocilizumab Use
Summary Table
fidaxomicin,
tocilizumab,
vancomycin
clostridium difficile
Use of Dronedarone HCL
Summary Table
Incident and Prevalent Dispensings of Mirabegron
Summary Table
Use of Ospemifene, Boceprevir, and Telaprevir
Summary Table
boceprevir,
ospemifene,
telaprevir
Prevalent and Incident Use of Testosterone Products
Summary Table
Top 100 Procedures and Diagnoses 30 Days Surrounding Incident Warfarin Use
Mini-Sentinel
Anti-Tumor Necrosis Factor (TNF) Utilization Among Pregnant Women
Descriptive
adalimumab,
certolizumab,
etanercept,
golimumab,
infliximab,
tumor necrosis factor (TNF) alpha inhibitor
Prevalent and Incident Use of Romiplostim
Summary Table
Suicide Diagnoses
Summary Table
Incident and Prevalent Use of Generic Drugs for Overactive Bladder
Summary Table
darifenacin hydrobromide,
fesoterodine fumarate,
oxybutynin chloride,
solifenacin succinate,
tolterodine tartrate,
trospium chloride
Use of Cancer Drugs
Summary Table
crizoatinib,
erlotinib HCL,
ipilimumab,
nivolumab,
pembrolizumab
Antipsychotic Use and Dementia Diagnoses
Summary Table
Genetic Testing Procedures
Summary Table
Atrial Fibrillation Prevalence
Summary Table
atrial fibrillation
atrial flutter
Mycophenolate Dispensings and Procedures
Summary Table
mycophenolate mofetil,
mycophenolate mofetil HCL,
mycophenolate sodium
Mycophenolate Dispensings and Procedures (by Quarter)
Summary Table
mycophenolate mofetil,
mycophenolate mofetil HCL,
mycophenolate sodium
Niacin and Fenofibrate Use and Outcomes with Propensity Score Matching
Mini-Sentinel
extended-release (ER) niacin,
fenofibrate
gastrointestinal (GI) bleed
intracranial hemorrhage
ischemic stroke
Stroke Following Typical or Atypical Antipsychotic Use in Non-Elderly Patients: A Propensity Score Matched Analysis
Retrospective Inferential
Stroke Following Atypical Antipsychotic or Z-Hypnotic Use in Patients with Prior Use of Selective Serotonin Reuptake Inhibitors (SSRIs): A Propensity Score Matched Analysis
Retrospective Inferential
aripiprazole,
fluoxetine,
olanzapine,
quetiapine,
risperidone
Antipsychotics and Stroke
Descriptive
aripiprazole,
atypical antipsychotic,
haloperidol,
olanzapine,
olanzapine/​fluoxetine,
quetiapine,
risperidone,
selective serotonin reuptake inhibitor (SSRI),
typical antipsychotic
intracranial hemorrhage
ischemic stroke
Sodium/Glucose Cotransporter (SGLT2) Inhibitors- Type 1 and Type 2 Diabetes Cohort Identification
Descriptive
dipeptidyl peptidase-4 (DPP-4) inhibitor,
sodium-glucose cotransporter-2 (SGLT-2) inhibitor,
sulfonylurea
diabetes
type 1 diabetes mellitus
type 2 diabetes mellitus
Niacin and Niacin Combination Products, Fenofibrates, and Omega-3 Products
Summary Table
fenofibrate,
niacin,
niacin/​lovastatin,
niacin/​simvastatin,
omega-3 product
Mirabegron Use
Summary Table
Alosetron Use
Summary Table
Pegylated Products Use
Summary Table
certolizumab pegol,
methoxy peg-epoetin beta,
pegademase bovine,
peginterferon beta-1a,
pegloticase,
pegvisomant
Pegylated Products Follow-Up Request
Summary Table
New Molecular Entities Approved in 2010-2015
Summary Table
abiraterone acetate,
aclidinium bromide,
ado-trastuzumab emtansine,
afatinib dimaleate,
albiglutide,
alcaftadine,
alectinib HCL,
alglucosidase alfa,
alirocumab,
alogliptin benzoate,
apixaban,
apremilast,
aripiprazole,
aripiprazole lauroxil,
asfotase alfa,
asparaginase,
avanafil,
axitinib,
azilsartan medoxomil,
bazedoxifene,
bedaquiline fumarate,
belatacept,
belimumab,
belinostat,
blinatumomab,
boceprevir,
bosutinib,
brexpiprazole,
cabazitaxel,
cabozantinib,
canagliflozin,
cangrelor tetrasodium,
carfilzomib,
carglumic acid,
cariprazine HCL,
ceftaroline fosamil acetate,
ceftazidime/​avibactam,
ceftolozane,
ceritinib,
cholic acid,
clobazam,
cobicistat,
cobimetinib fumarate,
collagenase clostridium histolyticum,
crofelemer,
dabigatran etexilate mesylate,
dabrafenib mesylate,
daclatasvir dihydrochloride,
dalbavancin HCL,
dalfampridine,
dapagliflozin propanediol,
daratumumab,
deferiprone,
denosumab,
deoxycholic acid,
dimethyl fumarate,
dinutuximab,
dolutegravir sodium,
droxidopa,
dulaglutide,
edoxaban tosylate,
efinaconazole,
eliglustat tartrate,
elosulfase alfa,
elotuzumab,
eluxadoline,
elvitegravir,
elvitegravir/​cobicistat/​emtricitabine/​tenofovir,
empagliflozin,
enzalutamide,
eribulin mesylate,
eslicarbazepine acetate,
estradiol valerate/​dienogest,
estrogen,
evolocumab,
ezogabine,
fidaxomicin,
fingolimod HCL,
flibanserin,
florbetapir f-18,
fluconazole,
flutemetamol f-18,
gabapentin enacarbil,
gadobutrol,
gadoterate meglumine,
glucarpidase,
ibrutinib,
icatibant acetate,
idarucizumab,
idelalisib,
incobotulinumtoxina,
indacterol maleate,
ingenol mebutate,
insulin degludec,
ioflupane i-123,
ipilimumab,
isavuconazonium sulfate,
ivabradine HCL,
ivacaftor,
ixazomib citrate,
ledipasvir,
lenvatinib mesylate,
linaclotide,
linagliptin,
liraglutide,
lomitapide mesylate,
lorcaserin HCl,
lucinactant,
luliconazole,
lumacaftor/​ivacaftor,
lurasidone HCL,
macitentan,
mepolizumab,
metreleptin,
miltefosine,
mipomersen sodium,
naloxegol oxalate,
necitumumab,
netupitant,
nintedanib esylate,
nivolumab,
obinutuzumab,
ocriplasmin,
olaparib,
olodaterol HCL,
omacetaxine mepesuccinate,
ombitasvir,
oritavancin diphosphate,
osimertinib mesylate,
ospemifene,
palbociclib,
palonosetron HCL,
panobinostat lactate,
parathyroid hormone,
paritaprevir,
pasireotide diaspartate,
patiromer calcium sorbitex,
peginterferon beta-1a,
pegloticase,
pembrolizumab,
peramivir,
pirfenidone,
pitavastatin,
polidocanol,
pomalidomide,
radium-223 dichloride,
ramucirumab,
rilpivirine HCL,
riociguat,
rivaroxaban,
roflumilast,
rolapitant HCL,
ruxolitinib phosphate,
sacubitril/​valsartan,
sebelipase alfa,
secukinumab,
selexipag,
siltuximab,
simeprevir sodium,
sofosbuvir,
sonidegib phosphate,
spinosad,
sugammadex sodium,
sulfur hexafluoride microsphere,
suvorexant,
tasimelteon,
tazobactam,
tedizolid phosphate,
teduglutide,
telaprevir,
tenofovir disoproxil fumarate,
teriflunomide,
tesamorelin acetate,
ticagrelor,
tocilizumab,
tofacitinib citrate,
trabectedin,
trametinib dimethyl sulfoxide,
trifluridine/​tipiracil HCL,
ulipristal acetate,
umeclidinium,
uridine,
vandetanib,
vedolizumab,
velaglucerase alfa,
vemurafenib,
vilanterol,
vilazodone HCL,
vismodegib,
vorapaxar sulfate,
vortioxetine hydrobromide,
ziv-aflibercept
Indications of Use Among Oral Antifungal Drug Users
Descriptive
fluconazole,
griseofulvin,
itraconazole,
ketoconazole,
terbinafine
Actemra (Tocilizumab) Utilization Among Pregnant Women
Descriptive
Actemra,
tocilizumab
juvenile rheumatoid arthritis
rheumatoid arthritis
Anti-epileptic Drugs and Angioedema
Descriptive
lacosamide,
lamotrigine,
levetiracetam,
oxcarbazepine,
phenytoin
Drug Use Following Genetic Testing Among Patients with Cancer
Descriptive
afatinib dimaleate,
BCR-ABL,
bosutinib,
BRAF,
BRCA,
cetuximab,
cobimetinib fumarate,
dabrafenib mesylate,
dasatinib,
erlotinib HCL,
estimated glomerular filtration rate (eGFR),
gefitinib,
imatinib mesylate,
KRAS,
nilotinib HCL,
olaparib,
osimertinib mesylate,
panitumumab,
ponatinib HCL,
trametinib dimethyl sulfoxide,
vemurafenib
Multiple Births and Preterm Deliveries
Descriptive
preterm delivery
Influenza Antiviral Drug Use 2010-2015
Descriptive
oseltamivir,
zanamivir
Prevalent Dispensings of Ticagrelor (Brilinta) and Vortioxetine Hydrobromide (Brintellix)
Summary Table
Brilinta,
Brintellix,
ticagrelor,
vortioxetine hydrobromide
Attention Deficit Hyperactivity Disorder (ADHD) Medications and Heart Failure
Descriptive
amphetamine,
methylphenidate,
Strattera
heart failure or cardiomyopathy
PROMPT: Mirabegron Surveillance
Prospective Sequential Inferential
mirabegron,
oxybutynin
acute myocardial infarction (AMI)
stroke
Dronedarone and Electrocardiograms
Descriptive
electrocardiogram
Parenteral Iron and Anaphylactoid Reactions
Custom Code
parenteral iron (IV iron)
anaphylactoid reaction
Dabigatran and Warfarin Use Among Members with Atrial Fibrillation and Other Pre-Existing Conditions
Descriptive
dabigatran,
warfarin
MRI and GBCA Procedures
Descriptive
Hysterectomy Procedures Among Females
Descriptive
hysterectomy
morcellation
uterine fibroid
Most Frequent Generic Dispensings Among Members Aged 65+
Descriptive
Immunoglobulin Products and Hemolysis
Mini-Sentinel
Incident Testosterone Indication Diagnoses and Testosterone Use
Mini-Sentinel
Hypogonadism and Testosterone Use
Mini-Sentinel
Incident Testosterone Use
Mini-Sentinel
New Use of Statins and Rhabdomyolysis
Mini-Sentinel
atorvastatin,
fluvastatin,
lovastatin,
pitavastatin,
pravastatin,
rosuvastatin,
simvastatin,
statin
Epidural Steroid Use
Mini-Sentinel
Serum Creatinine Procedures and Labs
Mini-Sentinel
Isotretinoin and Long-term Antibiotic Use and Multiple Sclerosis
Mini-Sentinel
abacavir,
doxycycline,
erythromycin,
isotretinoin,
lamivudine,
long-term antibiotic,
minocycline,
zidovudine
multiple sclerosis
Omalizumab or Montelukast Use Among Individuals with Asthma and Acute Myocardial Infarction, Stroke, Intracranial Hemorrhage, or Pulmonary Embolism
Mini-Sentinel
acute myocardial infarction (AMI)
intracranial hemorrhage
stroke
Laparoscopic Hysterectomy With and Without Robotic Assistance and Adverse Outcomes
Mini-Sentinel
laparoscopic hysterectomy
intraoperative complication
medical complication
surgical site complication
New Use of Dabigatran or Warfarin and Gastrointestinal Hemorrhage or Intracerebral Hemorrhage Events
Mini-Sentinel
dabigatran,
warfarin
gastrointestinal hemorrhage
intracerebral hemorrhage (ICH)
New Use of Anti-Epileptic Drugs and Agranulocytosis
Mini-Sentinel
anti-epileptic drug (AED),
carbamazepine,
lamotrigine,
levetiracetam,
topiramate
absolute neutrophil count (ANC)
agranulocytosis
IVIg Product Use and Hemolysis Events
Mini-Sentinel
flebogamma,
Gammagard,
Gammaplex,
Gamunex,
intravenous immunoglobulin (IVIg),
Octagam,
Privigen
Incident Use of Testosterone Products Among All Members and Members with Pre-Existing Testosterone Use
Mini-Sentinel
Androgel,
Axiron,
Fortesta,
intramuscular testosterone,
methyltestosterone,
Striant,
Testim,
testosterone,
testosterone cypionate,
testosterone enanthate,
testosterone pellet,
testosterone propionate,
testosterone suspension,
transdermal testosterone
Concomitant Use of Niacin and Statins and Concomitant Use of Fenofibrates and Statins
Mini-Sentinel
fenofibrate,
niacin,
statin
Anticoagulant Use Among Members with Atrial Fibrillation and Various Pre-Existing Exlusions
Mini-Sentinel
anticoagulant,
dabigatran,
warfarin
Anticoagulant Use Among Members with Pre-Existing Atrial Fibrillation and Various Pre-Existing Exclusions
Mini-Sentinel
anticoagulant,
dabigatran,
warfarin
Anticoagulants and Bleeding Events
Mini-Sentinel
anticoagulant,
dabigatran,
warfarin
Antidepressant Use and Bleeding Events
Mini-Sentinel
antidepressant,
selective serotonin reuptake inhibitor (SSRI),
serotonin-norepinephrine reuptake inhibitor (SNRI),
tricyclic
bleeding event
gastrointestinal hemorrhage
intracerebral hemorrhage (ICH)
Dabigatran Uptake and Persistence
Mini-Sentinel
Incident Antipsychotic Use
Mini-Sentinel
antipsychotic,
aripiprazole,
asenapine,
clozapine,
iloperidone,
lurasidone,
olanzapine,
paliperidone,
quetiapine,
risperidone,
ziprasidone
Indications of Intravenous Immunoglobulin Use
Mini-Sentinel
intravenous immunoglobulin (IVIg)
Anticoagulant Use Among Patients with Atrial Fibrillation
Descriptive
anticoagulant,
dabigatran,
oral formulation of apixaban,
rivaroxaban,
warfarin
Drug Use Among Pregnant Women with Live Births
Mini-Sentinel
angiotensin-converting enzyme (ACE) inhibitor,
anticonvulsant,
dabigatran,
lisinopril,
methotrexate,
mycophenolate mofetil,
paroxetine,
ribavirin,
selective serotonin reuptake inhibitor (SSRI),
simvastatin,
sodium valproate,
statin,
valproic acid,
warfarin
Anti-Diabetes Drugs and Acute Myocardial Infarction, Hospitalized Heart Failure
Mini-Sentinel
anti-diabetic agent (ADA),
dipeptidyl peptidase-4 (DPP-4) inhibitor,
glimepiride,
glipizide,
glyburide,
hypoglycemic drug,
long-acting insulin,
pioglitazone,
saxagliptin,
sitagliptin,
sulfonylurea,
thiazolidinedione
acute myocardial infarction (AMI)
heart failure
Select Bisphosphonates and Select Outcomes of Interest
Mini-Sentinel
esophageal cancer
fractures
hip fracture
non-vertebral fracture
osteonecrosis of the jaw
Anaphylaxis Events Following Incident Vaccine Exposure Among Members with a Pre-Existing Condition of Milk Allergy
Mini-Sentinel
diphtheria, tetanus, acellular pertussis (DTaP) vaccine,
diphtheria, tetanus, acellular pertussis (DTaP)-haemophilus influenzae type B (HIB) vaccine,
diphtheria, tetanus, acellular pertussis (DTaP)-haemophilus influenzae type B (HIB)-inactivated polio vaccine (IPV),
diphtheria, tetanus, acellular pertussis (DTaP)-hepatitis B (Hep B)-inactivated polio vaccine (IPV),
diphtheria, tetanus, acellular pertussis (DTaP)-inactivated polio vaccine (IPV),
tetanus, diphtheria, pertussis (Tdap) vaccine
anaphylactic shock
Omalizumab Use
Mini-Sentinel
Prevalent and Incident Use of Pramipexole
Mini-Sentinel
Hypoglycemic Events Following Use of Anti-Diabetic Agents (ADAs)
Mini-Sentinel
anti-diabetic agent (ADA),
chlorpropamide,
glimepiride,
glipizide,
glipizide/​metformin,
glyburide,
glyburide/​metformin,
insulin,
metformin,
pioglitazone,
pioglitazone/​metformin,
rosiglitazone maleate,
rosiglitazone/​metformin,
tolazamide
Omalizumab and Montelukast Use
Mini-Sentinel
montelukast,
omalizumab
Gastrointestinal Disorders
Mini-Sentinel
entercolitis
gastrointestinal disorder
ileocolitis
procitis
proctosigmoiditis
pseudopolyposis
regional enteritis
ulcerative colitis
Injection Omalizumab Procedure Codes
Mini-Sentinel
Progressive Multifocal Leukoencephalapathy
Mini-Sentinel
progressive multifocal leukoencephalopathy (PML)
Methotrexate and Tofacitinib Use
Mini-Sentinel
methotrexate,
methotrexate sodium,
methotrexate sodium, preservative free,
tofacitinib citrate
Incident and Prevalent Use of Alvimopan, Naltrexone, and Methylnaltrexone
Mini-Sentinel
alvimopan,
methylnaltrexone bromide,
morphine sulfate/​naltrexone,
naltrexone,
naltrexone HCL,
naltrexone microsphere
Procedure Codes Related to Memory Gel Breast Implants
Mini-Sentinel
Opioid Medication Use
Mini-Sentinel
Buprenex,
Butrans,
generic injectable buprenorphine,
generic oral buprenorphine,
generic powder buprenorphine,
opioid,
Suboxone,
Subutex
Buprenorphine Product Use
Mini-Sentinel
CPAX Aneurysm Procedure Codes
Mini-Sentinel
CPAX aneurysm
emboli detection
intravenous microbubble injection
surgery of intracranial aneurysm
transcranial doppler study
Lap-band Diagnosis Codes
Mini-Sentinel
bariatric surgery
gastric band procedure
Activa Tremor Control Procedures
Mini-Sentinel
Activa Tremor Control
Ascension Metacarpophalangeal Diagnoses
Mini-Sentinel
Ascension metacarpophalangeal (MCP)
arthritis
diffuse disease of connective tissue
osteoarthritis
sprain and strain of metacarpophalangeal of hand
traumatic arthropathy
Ascension Metacarpophalangeal Procedures
Mini-Sentinel
arthroplasty metacarpophalangeal interphalangeal joint
arthrotomy for removal of prosthesis
division of joint
CPAX Aneurysm Diagnoses
Mini-Sentinel
CPAX aneurysm
aneurysm
arthropod-borne hemorrhagic fever
cerebral aneurysm nonruptured
intracerebral hemorrhage (ICH)
mosquito-borne viral encephalitis
subarcahnoid hemorrhage
Activa Tremor Control Diagnoses
Mini-Sentinel
Activa Tremor Control
essential tremor
other specified forms of tremor
paralysis agitans
Dialysis HCPCS Procedure Codes
Mini-Sentinel
dialysis
end-stage renal disease (ESRD)
kidney failure
Dialysis ICD9 Procedure Codes
Mini-Sentinel
dialysis
end-stage renal disease (ESRD)
kidney failure
Dialysis ICD9 Diagnosis Codes
Mini-Sentinel
dialysis
end-stage renal disease (ESRD)
kidney failure
Anti-Infective Agents Use 2
Mini-Sentinel
anti-infective agent
Cardiovascular Therapy Agent Use 2
Mini-Sentinel
acebutolol HCL,
cardiovascular therapy agent
Gastrointestinal Therapy Agents Use 2
Mini-Sentinel
gastrointestinal therapy agent
Antiepileptic Drugs (AEDs) and Kidney Stones 2
Mini-Sentinel
anti-epileptic drug (AED),
carbamazepine,
gabapentin,
lamotrigine,
levetiracetam,
oxcarbazepine,
phenytoin,
topiramate,
valproic acid,
zonisamide
Infectious Disease Diagnoses
Mini-Sentinel
Chagas disease
anthrax
ascariasis
hepatitis
hepatitis C
hookworm
influenza
leishmaniasis
malaria
methicillin-resistant Staphylococcus aureus (MRSA)
plague
schistosomiasis
trichuriasis
tuberculosis (TB)
tularemia
Occurrence of Selected Generic Drugs 12
Summary Table
Analgesic Use 3
Summary Table
Diabetes Diagnoses and Occurrence of Laboratory Results
Mini-Sentinel
Anti-D, Dexamethasone, Prednisone, Romiplostim and Hemolysis
Mini-Sentinel
anti-D,
dexamethasone,
prednisone,
romiplostim
Immune Globulin Use
Summary Table
immune globulin, gamma (IgG),
immune globulin, gamma (IgG)/maltose,
immune globulin, gamma caprylate (IgG)
Injection Gammagard Use
Summary Table
Hemorrhagic Disorder Diagnoses
Summary Table
acquired hemophilia
hemorrhagic disorder
Occurrence of Kidney Stones
Mini-Sentinel
anti-diabetic agent (ADA)
Hemodialysis Procedures
Summary Table
Enoxaparin Sodium Use
Summary Table
Injection Enoxaparin Sodium Use
Summary Table
Acute Kidney Failure Diagnoses
Summary Table
acute kidney failure
Occurrence of Selected Dental HCPCS Codes
Summary Table
Nursing Home Facility HCPCS Codes
Summary Table
Prevalent and Incident Use of Acetazolamide
Summary Table
Long Acting Beta2-Agonists (LABA) Policies and Drug Utilization Patterns
Mini-Sentinel
long-acting beta2 agonist (LABA)
change in drug utilization patterns
Prevalent and Incident Use of Quinine Sulfate
Mini-Sentinel
Quinine Sulfate, Diltiazem and Selected Thrombotic Events
Mini-Sentinel
diltiazem,
quinine sulfate
hemolytic-uremic syndrome
immune thrombocytopenic purpura
other secondary thrombocytopenia
thrombotic microangiopathy
unspecified thrombocytopenia
Anti-Seizure Medication Use
Mini-Sentinel
carbamazepine,
ethosuxamide,
felbamate,
gabapentin,
lamotrigine,
levetiracetam,
oxcarbazepine,
phentermine HCl,
phentermine resin,
phenytoin,
phenytoin sodium,
phenytoin sodium extended,
pregabalin,
tiagabine HCL,
topiramate,
valproic acid,
zonisamide
Occurrence of Selected Generic Drugs 11
Mini-Sentinel
benzyl alcohol,
boceprevir,
dabigatran etexilate mesylate,
eltrombopag olamine,
febuxostat,
pitavastatin calcium,
Pradaxa,
rivaroxaban,
telaprevir,
vigabatrin
Multiple Sclerosis Medication Use
Mini-Sentinel
fingolimod HCL,
glatiramer acetate,
interferon beta-1A,
interferon beta-1A/​albumin,
interferon beta-1B,
mitoxantrone HCL,
natalizumab
Multiple Sclerosis Medication Injections
Mini-Sentinel
injection glatiramer acetate,
injection interferon beta-1A,
injection interferon beta-1A,
injection interferon beta-1B,
injection mitoxantrone HCL,
injection natalizumab
Antiepileptic Drugs (AEDs) and Kidney Stones
Mini-Sentinel
anti-epileptic drug (AED),
carbamazepine,
gabapentin,
lamotrigine,
levetiracetam,
oxcarbazepine,
phenytoin,
topiramate,
zonisamide
Nursing Home HCPCS Codes
Mini-Sentinel
Chronic Kidney Disease Diagnoses
Mini-Sentinel
chronic kidney disease (CKD)
Oral Antifungal Use
Mini-Sentinel
fluconazole,
itraconazole,
ketoconazole,
posaconazole,
terbinafine,
voriconazole
Occurrence of Selected Generic Drugs 10
Mini-Sentinel
allopurinol,
diclofenac,
isoniazid,
lapatinib,
telithromycin,
ticlopidine
Antiepileptic Drug Use
Mini-Sentinel
acetazolamide,
carbamazepine,
clobazam,
clonazepam,
diazepam,
ethosuxamide,
ezogabine,
felbamate,
gabapentin,
lacosamide,
lamotrigine,
levetiracetam,
lorazepam,
oxcarbazepine,
phenobarbital,
phenytoin,
pregabalin,
primidone,
rufinamide,
tiagabine,
topiramate,
valproic acid,
vigabatrin,
zonisamide
Propylthiouracil and Methimazole Use 2
Mini-Sentinel
methimazole,
propylthiouracil
Unspecified Anterior Pituitary Hyperfunction and Hypertrophy of the Breast Diagnoses
Mini-Sentinel
anterior pituitary hyperfunction
hypertrophy
HIV and HBV Infection Diagnoses
Mini-Sentinel
hepatitis B virus (HBV)
human immunodeficiency virus (HIV)
Bupropion HCL Sustained Release HCPCS Codes
Mini-Sentinel
bupropion HCL sustained release tablet
Occurrence of Selected Generic Drugs 9
Mini-Sentinel
ezetimibe/​simvastatin,
lisinopril,
lisinopril/​dietary sup. Cmb10,
lisinopril/​hydrochlorothiazide,
methotrexate,
methotrexate sodium,
mycophenolate mofetil,
mycophenolate sodium,
niacin/​simvastatin,
paroxetine HCL,
paroxetine mesylate,
ribavirin,
ribavirin/​interferon alfa-2B,
simvastatin,
valproic acid,
warfarin sodium
Analgesic Use 2
Mini-Sentinel
acetaminophen with codeine,
aspirin/​codeine phosphate,
codeine phosphate,
codeine sulfate,
fentanyl citrate,
methadone HCL,
morphine sulfate,
oxycodone HCL,
oxymorphone HCL,
sulindac,
tramadol HCL
Anti-Infective Agents Use
Mini-Sentinel
acyclovir,
acyclovir sodium,
atovaquone,
doxycycline calcium,
doxycycline hyclate,
nitazoxanide,
norfloxacin,
telithromycin,
tenofovir disoproxil fumarate
Cardiovascular Therapy Agents Use
Mini-Sentinel
acebutolol HCL,
aliskiren hemifumarate,
ambrisentan,
amlodipine besylate,
atenolol,
betaxolol HCL,
bosentan,
captopril,
carvedilol,
conivaptan HCL,
diltiazem HCL,
eprosartan mesylate,
indapamide,
labetalol HCL,
lisinopril,
metoprolol succinate,
metoprolol tartrate,
metoprolol/​hydrochlorothiazide,
nadolol,
nimodipine,
perindopril erbumine,
propafenone HCL,
trandolapril,
triamterene
Gastrointestinal Therapy Agents Use
Mini-Sentinel
aprepitant,
cimetidine,
dexlansoprazole,
dicyclomine HCL,
fosaprepitant dimeglumine,
lubiprostone,
mesalamine,
nizatidine,
sucralfate
Occurrence of Selected Generic Drugs 8
Mini-Sentinel
alosetron HCL,
alvimopan,
ambrisentan,
bosentan,
buprenorphine HCL,
bupropion HCL,
isotretinoin,
lenalidomide,
metoclopramide HCL,
naloxone HCL,
nilotinib HCL,
propoxyphene HCL,
propoxyphene HCL/​acetaminophen,
propoxyphene HCL/​ASA/​caffeine,
ribavirin/​interferon alfa-2B,
rosiglitazone/​glimepiride,
rosiglitazone/​metformin HCL,
sacrosidase,
sibutramine HCL,
thalidomide,
varenicline tartrate
Occurrence of Selected Generic Drugs 7
Mini-Sentinel
albuterol,
albuterol sulfate,
alvimopan,
calcium acetate,
chlorambucil,
cyclosporine,
cyclosporine modified,
levalbuterol HCL,
levalbuterol tartrate,
lindane,
phytonadione,
solifenacin succinate,
tretinoin,
vorinostat
Parkinson’s Disease Medication Use
Mini-Sentinel
carbidopa,
combination product of carbidopa,
entacapone,
levodopa,
levodopa and entacapone (Stalevo)
Oxicam NSAIDs, Modafinil/Armodafinil, Sulfamothoxazole and Severe Cutaneous Adverse Reaction (SCAR) Events
Mini-Sentinel
modafinil,
modafinil/​armodafinil,
oxicam,
sulfamothoxazole
severe cutaneous adverse reaction (SCAR)
Angiotensin Receptor Blockers (ARBs), Hydrochlorothiazide, Atenolol, Amlodipine Use and Celiac Disease
Mini-Sentinel
amlodipine,
angiotensin II receptor blocker (ARB),
atenolol,
candesartan,
eprosartan,
hydrochlorothiazide (HCTZ),
irbesartan,
losartan,
olmesartan,
telmisartan,
valsartan
Occurrence of Selected Pediatric Drugs 1
Mini-Sentinel
acetaminophen with codeine,
acyclovir,
albuterol,
nizatidine,
sucralfate
Vascular Endothelial Growth Factor (VEGF) Inhibitor Prevalent and Incident Use
Mini-Sentinel
bevacizumab,
sorafenib,
sunitinib,
thalidomide,
vascular endothelial growth factor (VEGF) inhibitor
Dabigatran, Rivaroxaban, and Warfarin Use
Mini-Sentinel
dabigatran,
rivaroxaban,
warfarin
Dabigatran, Warfarin and GI Bleed, Intracerebral Hemorrhage
Mini-Sentinel
dabigatran,
warfarin
gastrointestinal hemorrhage
intracerebral hemorrhage (ICH)
serious bleeding
Warfarin and GI Bleed, Intracerebral Hemorrhage
Mini-Sentinel
gastrointestinal hemorrhage
intracerebral hemorrhage (ICH)
serious bleeding
Dabigatran (Pradaxa), Warfarin and Gastrointestinal Bleed, Intracerebral Hemorrhage
Mini-Sentinel
anticoagulant,
blood thinner,
Coumadin,
dabigatran,
Pradaxa,
warfarin
gastrointestinal hemorrhage
intracerebral hemorrhage (ICH)
serious bleeding
Natalizumab, Efalizumab, and Progressive Multifocal Leukoencephalopathy (PML)
Mini-Sentinel
efalizumab,
natalizumab
progressive multifocal leukoencephalopathy (PML)
Selgiline Use
Mini-Sentinel
Lindane Use Modular Program
Mini-Sentinel
Bupropion and Naltrexone Use 1
Mini-Sentinel
bupropion,
naltrexone
Duloxetine, Pregabalin, and Milnacipran Use 1
Mini-Sentinel
duloxetine,
milnacipran,
pregabalin
Duloxetine, Pregabalin, and Milnacipran Use 2
Mini-Sentinel
duloxetine,
milnacipran,
pregabalin
Clopidogrel and Prasugrel Use
Mini-Sentinel
clopidogrel,
prasugrel
Bupropion and Naltrexone Use 2
Mini-Sentinel
bupropion,
naltrexone
Amphotericin Use
Mini-Sentinel
amphotericin B,
amphotericin B cholesteryl sulfate,
amphotericin B lipid complex,
amphotericin B liposome
Isoniazid Use
Mini-Sentinel
isoniazid,
rifampin/​isoniazid,
rifampin/​isoniazid/​pyrazinamid
Boceprevir and Telaprevir Use
Mini-Sentinel
boceprevir,
telaprevir
Injection Amphotericin Procedures
Mini-Sentinel
injection amphotericin B,
injection amphotericin B cholesteryl,
injection amphotericin B lipid complex,
injection amphotericin B lipid form,
injection amphotericin B liposome
Hip Implant Procedures and Diagnoses 2
Mini-Sentinel
acetabular component
acquired hemophilia
femoral component
mechanical complication of internal orthopedic device implant and graft
partial hip replacement
total hip replacement
Occurrence of Selected Generic Drugs 6
Mini-Sentinel
abacavir sulfate,
didanosine,
didanosine/​calcium carb/​mag,
didanosine/​sodium citrate,
efavirenz/​emtricitab/​tenofovir,
emtricitabine,
emtricitabine/​tenofovir,
entecavir,
lamivudine,
stavudine,
tenofovir disoproxil fumarate,
zidovudine
Nucleoside Reverse Transcriptase Inhibitor Procedures
Mini-Sentinel
didanosine,
injection zidovudine,
zidovudine oral
Golimumab, Ustekinumab, and Dronedarone Hydrochloride Use (by Quarter)
Mini-Sentinel
dronedarone HCL,
golimumab,
ustekinumab
Occurrence of Selected Generic Drugs 5
Mini-Sentinel
alosetron HCL,
ambrisentan,
bosentan,
buprenorphine HCL,
eltrombopag olamine,
fentanyl,
hydromorphone HCL,
isotretinoin,
lenalidomide,
mifepristone,
oxycodone HCL,
romiplostim,
rosiglitazone maleate,
rosiglitazone/​glimepiride,
rosiglitazone/​metformin HCL,
thalidomide,
vigabatrin
Natalizumab and Efalizumab Use
Mini-Sentinel
efalizumab,
natalizumab
Occurrence of Selected Generic Drugs 3
Mini-Sentinel
alosetron HCL,
ambrisentan,
bosentan,
buprenorphine HCL,
fentanyl,
hydromorphone HCL,
isotretinoin,
lenalidomide,
methadone HCL,
morphine sulfate,
naloxone HCL,
oxycodone HCL,
rosiglitazone maleate,
rosiglitazone/​glimepiride,
rosiglitazone/​metformin HCL,
thalidomide
Golimumab, Ustekinumab, and Dronedarone Hydrochloride Use (by Year)
Mini-Sentinel
dronedarone HCL,
golimumab,
ustekinumab
Injection Ustekinumab and Injection Denosumab Procedures
Mini-Sentinel
injection ustekinumab
Injection Natalizumab Procedures
Mini-Sentinel
injection natalizumab
Occurrence of Selected Generic Drugs 4
Mini-Sentinel
meloxicam,
modafinil,
piroxicam,
sulfamethoxazole,
trimethoprim-sulfamethoxazole
Drugs that Act on the Renin-Angiotensin-Aldosterone System (Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Aliskiren) and Angioedema
Mini-Sentinel
aliskiren,
angiotensin II receptor blocker (ARB),
angiotensin-converting enzyme (ACE) inhibitor
Occurrence of Selected Generic Drugs 1
Mini-Sentinel
azathioprine,
azathioprine sodium,
benzonatate,
cabergoline,
everolimus,
lopinavir/​ritonavir,
mercaptopurine,
ralegravir potassium,
ribavirin,
ribavirin A-2B,
tenofovir disoproxil fumarate,
tolvaptan,
voriconazole
Occurrence of Selected HCPCS Codes 1
Mini-Sentinel
cabergoline oral,
combination peginterferon and ribavirin,
mercaptopurine oral,
negative pressure wound therapy (NPWT)
Infliximab Use
Mini-Sentinel
Injection Infliximab Procedures
Mini-Sentinel
injection infliximab
Analgesics Use
Mini-Sentinel
Dalfampridine Use
Mini-Sentinel
Propylthiouracil and Methimazole Use
Mini-Sentinel
methimazole,
propylthiouracil
Occurrence of Selected Generic Drugs 2
Mini-Sentinel
acitretin,
acitretin/​emollient combo. 26,
ambrisentan,
bosentan,
busulfan,
chlorambucil,
clarithromycin,
cyclophosphamide,
dronedarone,
finasteride,
fluconazole,
isotretinoin,
lenalidomide,
lisinopril,
lisinopril/​hydrochlorothiazide,
lithium carbonate,
lithium citrate,
methimazole,
methotrexate,
methotrexate sodium,
telavancin,
thalidomide,
topiramate,
trastuzumab,
valproic acid,
warfarin
Occurrence of Selected HCPCS Codes 2
Mini-Sentinel
busulfan,
chlorambucil,
cyclophosphamide,
finasteride,
methotrexate,
trastuzumab
Lindane Use Summary Table
Summary Table
Regional Enteritis and Ulcerative Enterocolitis Diagnoses
Mini-Sentinel
Crohn's disease
regional enteritis
ulcerative enterocolitis
Arthritis Diagnoses
Mini-Sentinel
Felty's syndrome
arthritis
inflammatory polyarthropathy
juvenile chronic polyarthritis
rheumatoid arthritis
Use of Vascular Endothelial Growth Factor (VEGF) Inhibitors
Mini-Sentinel
bevacizumab,
sorafenib tosylate,
sunitinib malate,
thalidomide,
vascular endothelial growth factor (VEGF) inhibitor
Bone Resorption Inhibitor Use (by Drug Class)
Mini-Sentinel
bone resorption inhibitor
VEGF and Bone Resorption Inhibitor Procedures
Mini-Sentinel
bone resorption inhibitor procedure
vascular endothelial growth factor (VEGF)
Clozapine Use
Mini-Sentinel
Negative Pressure Wound Therapy (NPWT) Procedures
Mini-Sentinel
negative pressure wound therapy (NPWT)
Milk Allergy Diagnoses
Mini-Sentinel
Hip Implant Procedures and Diagnoses
Mini-Sentinel
arthroplasty
hemiarthroplasty
hip implant
hip replacement
Progressive Multifocal Leukoencephalopathy Diagnoses
Mini-Sentinel
progressive multifocal leukoencephalopathy (PML)
Hyperlipidemia Diagnoses
Mini-Sentinel
hypercholesterolemia
hyperchylomicronemia
hyperglyceridemia
hyperlipidemia
Heart/Lung Resuscitation (CPR), Injection Diphenhydramine Hydrochloride (HCL), Injection Adrenaline Epinephrine Procedures
Mini-Sentinel
injection adrenaline epinephrine,
injection diphenhydramine hydrochloride (HCL)
cardiopulmonary resuscitation (CPR)
Unspecified Allergic Reaction Diagnoses
Mini-Sentinel
unspecified allergic reaction
Cardiopulmonary Resuscitation (CPR) Not Otherwise Specified Procedures
Mini-Sentinel
cardiopulmonary resuscitation (CPR)
Asthma Diagnoses
Mini-Sentinel
Acute Myocardial Infarction Diagnoses
Mini-Sentinel
acute myocardial infarction (AMI)
Serious Cutaneous Adverse Reaction (SCAR) Diagnoses
Mini-Sentinel
severe cutaneous adverse reaction (SCAR)
Aseptic Necrosis of Bone Jaw Diagnoses
Mini-Sentinel
aseptic necrosis of bone jaw
Angiotensin II Receptor Blockers and Celiac Disease
Mini-Sentinel
angiotensin II receptor blocker (ARB),
candesartan,
eprosartan,
irbesartan,
losartan,
olmesartan,
telmisartan,
valsartan
Smoking Cessation Drugs and Cardiovascular Outcomes
Mini-Sentinel
bupropion,
varenicline
acute coronary occlusion without myocardial infarction
acute myocardial infarction (AMI)
cardiovascular outcome
intermediate coronary syndrome
unstable angina